Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solriamfetol in Adolescents With ADHD
NCT07717892Phase 3Recruiting
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 3 trial of solriamfetol in attention deficit hyperactivity disorder (ADHD), sponsored by Axsome Therapeutics, Inc.. Started Jun 2026; status: recruiting.
02
Drugs
solriamfetol
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT07717892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07717892.